The Sacklers, Jewish family behind OxyContin, will pay $6 billion in deal that shields them from lawsuits
Many institutions dropped the Sackler name as lawsuits over the opioid epidemic piled up, but Tel Aviv University has resisted pressure to do so
The Sackler name was on a number of institutions, including this wing at the Metropolitan Museum of Art in New York City that hours the famed Egyptian Temple of Dendur. (Spencer Platt/Getty Images)
(JTA) – The Sackler family, the Jewish billionaires whose marketing of the painkiller drug OxyContin fueled the United States’ ongoing opioid epidemic, will receive full immunity from all civil legal claims in exchange for spending up to $6 billion on addiction treatment and prevention programs.
The decision to grant immunity by a federal appeals court panel Tuesday effectively ends the thousands of civil lawsuits that have been filed against Purdue Pharma, the Sacklers’ company, over opioid deaths.
But it clears the way for the company to declare bankruptcy, a move considered essential to a plan to pay out billions of dollars to help states and communities address the opioid crisis. Of the up to $6 billion allocated under the deal, about $750 million, will go to people who became addicted to OxyContin and to family members of people who died from overdoses.
The ruling reverses a lower court’s 2021 ruling that bankruptcy proceedings were an improper tool for shielding wealthy private citizens from legal repercussions. It does not grant members of the Sackler family immunity against possible future criminal charges.
Purdue founders Arthur, Mortimer and Raymond Sackler were the sons of Jewish immigrants in Brooklyn who attended medical school in Scotland because American schools wouldn’t admit Jews at the time. Mortimer and Raymond introduced OxyContin in 1996, after Arthur had left the company; the family then made billions by aggressively marketing the drug for more than two decades, even amid signs it was driving users into opiate addiction.
The three brothers have all died, but other members of the family have retained control of Purdue Pharma and their wealth, estimated at about $11 billion two years ago.
The Sackler name had been a regular presence in philanthropic circles until the opioid lawsuits began building up in 2019, at which point many cultural institutions began refusing the family’s donations and removing their name from buildings. The Jewish artist and activist Nan Goldin spearheaded a grassroots movement opposing the family for years.
One notable beneficiary of the Sacklers, Tel Aviv University, has resisted pressure to drop the Sackler name from its medical school — though the American-facing wing of its medical school quietly removed the Sackler name from its marketing materials last year.
This article originally appeared on JTA.org.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.
If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.
— Rachel Fishman Feddersen, Publisher and CEO
